Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...